[{"orgOrder":0,"company":"Stamford Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-002","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Stamford Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Stamford Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stamford Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moffitt Cancer Center \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Ronald Buckanovich","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Ronald Buckanovich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ronald Buckanovich \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Ronald Buckanovich \/ Genentech"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ Sun Pharmaceutical Industries Limited"}]

Find Clinical Drug Pipeline Developments & Deals for Vismodegib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          November 04, 2024

                          Lead Product(s) : SP-002,Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 15, 2022

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University Hospital, Lille

                          Country arrow
                          EPSC
                          Not Confirmed

                          University Hospital, Lille

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 30, 2022

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Ronald Buckanovich

                          Country arrow
                          EPSC
                          Not Confirmed

                          Ronald Buckanovich

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 13, 2022

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SRH Wald-Klinikum Gera

                          Country arrow
                          EPSC
                          Not Confirmed

                          SRH Wald-Klinikum Gera

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2017

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University Hospital, Lille

                          Country arrow
                          EPSC
                          Not Confirmed

                          University Hospital, Lille

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 29, 2016

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University of Arizona

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Arizona

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 24, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Alliance for Clinical Trials in Oncology

                          Country arrow
                          EPSC
                          Not Confirmed

                          Alliance for Clinical Trials in Oncology

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 14, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          NYU College of Dentistry

                          Country arrow
                          EPSC
                          Not Confirmed

                          NYU College of Dentistry

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 19, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank